Product logins

Find logins to all Clarivate products below.


Anna Somuyiwa

Head of the Centre for Innovation in Regulatory Science

Anna has over 19 years’ experience in Regulatory Affairs, having worked with various pharmaceutical companies and Clinical Research Organizations.

She is responsible for the Centre for Innovation in Regulatory Science (CIRS), a neutral, independent UK-based subsidiary of Clarivate plc. Her responsibilities include setting and delivering the research strategy with CIRS members, stakeholders, and CIRS staff.


arrow_forward
Get in touch with Anna

Latest news

News April 29, 2025
Clarivate Reports First Quarter 2025 Results

— Accelerated recurring organic revenue growth — — Reaffirmed 2025 Outlook — — Repurchased $50 million ordinary shares — London, UK — April 29, 2025 Clarivate Plc (NYSE: CLVT) (the…

News April 23, 2025
Clarivate Launches DRG Commercial Analytics 360 Enabling Medtech Companies to Advance Commercial Strategy and Execution

New solution provides integrated provider intelligence and real-world data to optimize targeting, strategic planning and patient access across commercial organizations London, U.K. April 23, 2025: Clarivate Plc (NYSE:CLVT), a leading…

News April 23, 2025
Clarivate Releases EndNote 2025 with AI-Powered Research Tools

Enhancing research efficiency and accuracy with newly integrated features

Related resources

Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025
This small biotech notched a big win for rare disease patients with a canny market access strategy This small biotech notched a big win for rare disease patients with a canny market access strategy
Blog December 19, 2024
This small biotech notched a big win for rare disease patients with a canny market access strategy
Market Access